Moderna has received a six-month, $1.97B contract modification from the U.S. Army to manufacture 100M more doses of the company's messenger RNA vaccine against the novel coronavirus.
Army Contracting Command ordered additional filled drug production doses of the mRNA-1273 vaccine from the biotechnology firm by using the first option and acetate-related efforts under a previously awarded contract, the Department of Defense said Monday.
Cambridge, Massachusetts-based Moderna developed the vaccine with the National Institute of Allergy and Infectious Diseases and received an emergency use authorization from the Food and Drug Administration on Dec. 18.
The company received the full amount of the award and is expected to finish work under the modification by June 30.
DOD and the Department of Health and Human Services signed a $1.5B deal with Moderna in August to procure 100M initial vaccine doses of the vaccine.
